{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-019660","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-06-05T12:30:10+00:00","discovered_at":"2026-06-05T12:35:00.281878+00:00","generated_at":"2026-06-05T12:35:07.692166+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Moleculin announces strong physician intent to prescribe Annamycin in R/R AML; likelihood-to-prescribe score 6/7","bullets":["Oncologists reported average likelihood-to-prescribe Annamycin of 6 out of 7, citing deep remissions and reduced cardiotoxicity.","Physicians highlighted Annamycin's biomarker-agnostic applicability and potential to bridge patients to bone marrow transplant.","Payers viewed Annamycin as a potentially valuable addition for R/R AML, driven by efficacy and safety profile.","Key differentiators include MRD-negative responses and reduced cardiotoxicity, especially important for pediatric and repeat dosing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-019660","json":"https://secwatch.observer/filing/0001437749-26-019660.json","markdown":"https://secwatch.observer/filing/0001437749-26-019660.md","text":"https://secwatch.observer/filing/0001437749-26-019660.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926019660/0001437749-26-019660-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926019660/mbrx20260604_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T12:35:07.692166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}